Cancer clinical trials in the region Centre-Val de Loire

111 currently recruiting clinical trials
Region Centre-Val de Loire

Phase 3 Lung cancer #NCT06868277 #2024-517780-24-00
NSCLC (Non-Small Cell Lung Cancer) Metastatic PDL1 Positive (1% <= X < 25%) PDL1 Positive (25% <= X < 50%) PDL1 Positive (>= 50%) None Systemic Treatment-Naive
ALK EGFR ROS-1 Immunotherapy Immunotherapy
11 recruiting sites
AstraZeneca
Phase 3 Head and neck cancer #NCT06064877
Oral cavity Nasopharynx Oropharynx Hypopharynx Larynx Salivary glands Nasal cavities and sinuses Other Squamous cell carcinoma Locally Advanced Metastatic 1 2 Immunotherapy Chemotherapy
Systemic Treatment-Naive
6 recruiting sites
AVEO Pharmaceuticals, Inc.
Phase 3 Colon cancer Rectal cancer #NCT02885753
Adenocarcinoma Metastatic None Systemic Treatment-Naive
85 recruiting sites
Fédération Francophone de Cancérologie Digestive
Phase 3 Acute leukemia #NCT04307576 #2022-501050-11-01
Acute lymphoblastic leukemia (ALL) T-cell (T-ALL) B-cell (B-ALL) MYC None Systemic Treatment-Naive
28 recruiting sites
Karolinska University Hospital
Phase 3 Colon cancer #NCT02355379
Adenocarcinoma Locally Advanced None Systemic Treatment-Naive Surgery
Chemotherapy
113 recruiting sites
Fédération Francophone de Cancérologie Digestive
Phase 3 Colon cancer Rectal cancer #NCT04120701 #2024-515297-27-00
Adenocarcinoma Localized Locally Advanced None Systemic Treatment-Naive Surgery Systemic Treatment-Naive Surgery
Chemotherapy Radiotherapy Chemotherapy Radiotherapy
123 recruiting sites
CHU Dijon
Phase 3 Lung cancer #NCT05920356 #2022-501863-41-00
NSCLC (Non-Small Cell Lung Cancer) Non-squamous NSCLC Locally Advanced Metastatic KRAS G12C PDL1 Negative (< 1%) None Systemic Treatment-Naive
Targeted therapy Immunotherapy Chemotherapy Targeted therapy Car-T Bispecific T-cell engager antibodies Antibody Drug Conjugates (ADC)
27 recruiting sites
Amgen
Phase 3 Lung cancer #NCT06623422 #2023-506327-29-00
NSCLC (Non-Small Cell Lung Cancer) Localized Locally Advanced None Systemic Treatment-Naive Systemic Treatment-Naive
ALK EGFR Immunotherapy Immunotherapy
7 recruiting sites
Merck Sharp & Dohme LLC
Phase 3 Breast cancer #NCT06492616 #2024-515445-42-00
HER2 Negative HR Positive Localized None
Hormone therapy
21 recruiting sites
Stemline Therapeutics, Inc.